| pubmed-article:1449592 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1449592 | lifeskim:mentions | umls-concept:C0014792 | lld:lifeskim |
| pubmed-article:1449592 | lifeskim:mentions | umls-concept:C0001128 | lld:lifeskim |
| pubmed-article:1449592 | lifeskim:mentions | umls-concept:C0022203 | lld:lifeskim |
| pubmed-article:1449592 | pubmed:issue | 9-10 | lld:pubmed |
| pubmed-article:1449592 | pubmed:dateCreated | 1993-1-7 | lld:pubmed |
| pubmed-article:1449592 | pubmed:abstractText | The in vitro interaction of the [6S]- and [6R]-stereoisomers of CHO-THFA with human RBCs was investigated in the (therapeutically comparable) concentration range from 1.0 to 12.5 micrograms/ml. Both compounds are bound to RBCs with a kRBC ranging from 0.13 to 0.75 for [6S]-CHO-THFA and from 0.06 to 0.33 for [6R]-CHO-THFA, respectively. The interaction of the [6S]-form with RBCs is about two times higher than of the [6R]-form. Incubation of CHO-THFA with RBCs over 24 h showed an accelerated disappearance from the test solution for [6R]-CHO-THFA with a mean t1/2 of 49.9 h in compare to t1/2 = 58.2 h for the [6S]-enantiomer. The results indicate that RBCs may play a major role for the pharmacokinetics and metabolism of CHO-THFA and may act as an intravasal depot especially for [6S]-CHO-THFA. | lld:pubmed |
| pubmed-article:1449592 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1449592 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1449592 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1449592 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1449592 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1449592 | pubmed:issn | 0939-5075 | lld:pubmed |
| pubmed-article:1449592 | pubmed:author | pubmed-author:SchüllerJJ | lld:pubmed |
| pubmed-article:1449592 | pubmed:author | pubmed-author:ScheithauerWW | lld:pubmed |
| pubmed-article:1449592 | pubmed:author | pubmed-author:CzejkaM JMJ | lld:pubmed |
| pubmed-article:1449592 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1449592 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:1449592 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1449592 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1449592 | pubmed:pagination | 748-52 | lld:pubmed |
| pubmed-article:1449592 | pubmed:dateRevised | 2009-11-4 | lld:pubmed |
| pubmed-article:1449592 | pubmed:meshHeading | pubmed-meshheading:1449592-... | lld:pubmed |
| pubmed-article:1449592 | pubmed:meshHeading | pubmed-meshheading:1449592-... | lld:pubmed |
| pubmed-article:1449592 | pubmed:meshHeading | pubmed-meshheading:1449592-... | lld:pubmed |
| pubmed-article:1449592 | pubmed:meshHeading | pubmed-meshheading:1449592-... | lld:pubmed |
| pubmed-article:1449592 | pubmed:meshHeading | pubmed-meshheading:1449592-... | lld:pubmed |
| pubmed-article:1449592 | pubmed:meshHeading | pubmed-meshheading:1449592-... | lld:pubmed |
| pubmed-article:1449592 | pubmed:articleTitle | Red blood cell partitioning of the [6S]- and the [6R]-isomer of N5-formyltetrahydrofolic acid. | lld:pubmed |
| pubmed-article:1449592 | pubmed:affiliation | Institute for Pharmaceutical Chemistry, University of Vienna, Austria. | lld:pubmed |
| pubmed-article:1449592 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1449592 | pubmed:publicationType | Comparative Study | lld:pubmed |
